Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tectonic Therapeutic (TECX) EPS (Weighted Average and Diluted) (2021 - 2026)

Tectonic Therapeutic (TECX) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.34 in Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 44.09% to -$1.34 in Q1 2026 year-over-year; TTM through Mar 2026 was -$4.46, a 27.36% increase, with the full-year FY2025 number at -$4.05, up 40.7% from a year prior.
  • EPS (Weighted Average and Diluted) reached -$1.34 in Q1 2026 per TECX's latest filing, down from -$1.03 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TECX hit a ceiling of $0.33 in Q4 2024 and a floor of -$10.97 in Q1 2024.
  • A 5-year average of -$2.73 and a median of -$1.03 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 105.79% in 2024 and fell as far as 1824.56% in 2024.
  • Tracing TECX's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.57 in 2022, then tumbled by 900.0% to -$5.7 in 2023, then skyrocketed by 105.79% to $0.33 in 2024, then plummeted by 412.12% to -$1.03 in 2025, then tumbled by 30.1% to -$1.34 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TECX at -$1.34 in Q1 2026, -$1.03 in Q4 2025, and -$1.02 in Q3 2025.